Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that the Cutaneous Lupus Disease Area and Severity Index (CLASI) is correlated with both physician-assessed and patient-reported outcomes in cutaneous lupus erythematosus, particularly highlighting concerns about body image in visible areas.

This study found that while the CLASI is generally useful for assessing disease activity and damage in cutaneous lupus erythematosus, it may not accurately reflect all subtypes, indicating a need for revision.

In this multicenter study, belimumab effectively reduced disease activity in systemic lupus erythematosus patients with joint and skin manifestations, showing significant improvement in acute and subacute skin types earlier than in chronic types, while no significant benefit was observed for nonspecific skin manifestations.

This chapter reviews the development of skin-specific outcome instruments for autoimmune diseases like cutaneous lupus erythematosus and dermatomyositis, highlighting a need for a broader community-involved process across other diseases but reports no new results.

This article reviews the classification and treatment of cutaneous manifestations in systemic lupus erythematosus, highlighting the importance of monitoring for disease progression and reports no new clinical results.